During Week 48 of the 2023-2024 flu season, seasonal influenza activity continued to increase in most parts of the country, with the highest levels of activity reported in the southeast and south-central areas. In terms of viruses, clinical lab testing showed a predominance of influenza A(H1N1) viruses. Genetic and antigenic characterization of the viruses is ongoing. Outpatient illness surveillance indicated that 4.0% of patient visits were due to respiratory illness, above the national baseline. Activity levels varied by region, with some experiencing moderate to high ILI activity. Hospitalization rates increased, with a cumulative rate of 5.5 per 100,000 population. Pneumonia and influenza mortality remained stable below the epidemic threshold. No pediatric deaths from influenza have been reported during this season. It is recommended that everyone 6 months and older get vaccinated, and antiviral drugs are available for treatment.